论文部分内容阅读
胃癌就全世界而论,在癌症死亡原因中位居前茅。但涉及胃癌的化疗研究为数寥寥,且多以单独使用氟脲嘧啶(5-FU)为主。据他人统计,至1974年以前,搜集文献报道使用5-FU 治疗胃癌448例中客观显效率为22%。前此不久,著者观察到卡氮芥(BCNU)与5-FU 合用治疗胃癌比二者任一单独使用的效果都好,患者生存期亦相应延长;还发现甲基环己亚硝脲(me-CCNU)有可能比其它亚硝基脲类更好,又能口服。故美国东部癌协作组(ECOG)乃发起本研究。又鉴于有人提到 CTX 对胃癌有一时性疗效并与亚硝基脲类有协同相乘作用,故亦纳入本研究。参加本项工作共28个单位,按统一标准选择病人,共146例晚期胃癌,材料完整可供分析者为130例。凡合格患者随
As far as the world’s stomach cancer is concerned, it ranks among the leading causes of cancer death. However, the number of chemotherapy studies involving gastric cancer is several, and most of them use fluorouracil (5-FU) alone. According to statistics from other people, by 1974, it was reported that the objective effective rate in the use of 5-FU in the treatment of gastric cancer was 22%. Shortly before this, the authors observed that BCNU and 5-FU combined with gastric cancer were better than either one alone, and their survival time was prolonged accordingly; methylcyclohexyl nitrosourea (metriloamide) was also found. - CCNU) may be better than other nitrosoureas and can be taken orally. Therefore, the US Eastern Cancer Cooperative Group (ECOG) initiated the study. In view of the mention that CTX has a temporary effect on gastric cancer and synergistic effects with nitrosoureas, it is also included in this study. A total of 28 units participated in this work, and patients were selected according to uniform criteria. A total of 146 patients with advanced gastric cancer were enrolled in this study. There were 130 patients with complete materials available for analysis. All eligible patients